Recruiting
Study of BGB-43395 with letrozole versus CDK4/6 inhibitor drug combination with letrozole in patients with untreated advanced HR‑positive HER2‑negative breast cancer
Registered drugNo placebo
Study of BGB-43395 with letrozole versus CDK4/6 inhibitor drug combination with letrozole in patients with untreated advanced HR‑positive HER2‑negative breast cancer
Registered drugNo placebo
- Disease:Hormone receptor positive HER2 negative breast cancer
- Substances:AbemaciclibBGB-43395+4
Countries:
France
France- Participants:18–64 years · 65+ years
- Substances:Abemaciclib



